Pressler ML - Search Results

1

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.

Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lespérance J, Blue J, Heinonen T, Rodés-Cabau J; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Tardif JC, et al. Among authors: pressler ml. Circulation. 2004 Nov 23;110(21):3372-7. doi: 10.1161/01.CIR.0000147777.12010.EF. Epub 2004 Nov 8. Circulation. 2004. PMID: 15533865 Clinical Trial.

2

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA. Udelson JE, et al. Among authors: pressler ml. Circulation. 2001 Nov 13;104(20):2417-23. doi: 10.1161/hc4501.099313. Circulation. 2001. PMID: 11705818 Clinical Trial.

3

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.

Russell SD, Selaru P, Pyne DA, Ghazzi MM, Massey KD, Pressler M, Serikoff A, Coats AJ. Russell SD, et al. Am Heart J. 2003 Jan;145(1):179-86. doi: 10.1067/mhj.2003.39. Am Heart J. 2003. PMID: 12514672 Clinical Trial.

4

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Packer M, et al. Among authors: pressler ml. N Engl J Med. 1996 Oct 10;335(15):1107-14. doi: 10.1056/NEJM199610103351504. N Engl J Med. 1996. PMID: 8813041 Free article. Clinical Trial.

5

Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation.

Mohler ER 3rd, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, Cropp AB, Pressler ML. Mohler ER 3rd, et al. Among authors: pressler ml. J Am Coll Cardiol. 1997 Jul;30(1):35-41. doi: 10.1016/s0735-1097(97)00145-9. J Am Coll Cardiol. 1997. PMID: 9207618 Free article. Clinical Trial.

6

Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension.

Wolk R, Smith WB, Neutel JM, Rubino J, Xuan D, Mancuso J, Gilbert J, Pressler ML. Wolk R, et al. Among authors: pressler ml. Hypertension. 2009 Jun;53(6):1091-7. doi: 10.1161/HYPERTENSIONAHA.109.132225. Epub 2009 Apr 27. Hypertension. 2009. PMID: 19398651 Clinical Trial.

7

Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation.

O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. O'Connor CM, et al. Among authors: pressler ml. Am J Cardiol. 1998 Oct 1;82(7):881-7. doi: 10.1016/s0002-9149(98)00496-2. Am J Cardiol. 1998. PMID: 9781971 Clinical Trial.

8

The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.

Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, Pressler ML. Li JS, et al. Among authors: pressler ml. J Pediatr. 2010 Aug;157(2):282-7. doi: 10.1016/j.jpeds.2010.02.042. Epub 2010 Apr 18. J Pediatr. 2010. PMID: 20400095 Clinical Trial.

9

Diuretic resistance predicts mortality in patients with advanced heart failure.

Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M; PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Neuberg GW, et al. Among authors: pressler ml. Am Heart J. 2002 Jul;144(1):31-8. doi: 10.1067/mhj.2002.123144. Am Heart J. 2002. PMID: 12094185 Clinical Trial.

10

Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.

Rajagopalan S, Mohler E 3rd, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT; Regional Angiogenesis With Vascular Endothelial Growth Factor trial. Rajagopalan S, et al. Am Heart J. 2003 Jun;145(6):1114-8. doi: 10.1016/S0002-8703(03)00102-9. Am Heart J. 2003. PMID: 12796772 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page